{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:14:28Z","timestamp":1792782868524,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Public Health Research Foundation","id":[{"id":"https:\/\/ror.org\/04w7eg945","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Asahi Kasei Pharma Corp.","id":[{"id":"https:\/\/ror.org\/02fy54p06","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The goal of modern osteoporosis management is to prevent fractures and preserve patient quality of life (QOL). However, factors associated with changes in QOL during treatment, particularly for patients with severe osteoporosis, are not well understood. This study aimed to identify clinical and biochemical factors associated with the magnitude of QOL improvement in this high-risk population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This was a post hoc analysis of data from the Japan Osteoporosis Intervention Trial-05 (JOINT-05). The analysis included 612 women with severe osteoporosis, with a mean age of 81.3\u00a0years. The primary endpoint was the change in the EuroQol-5 dimensions (EQ-5D) utility score over 72\u00a0weeks. Potential baseline factors included patient demographics, oral health status (number of remaining teeth), low back pain intensity (visual analog scale, VAS), and biochemical markers. Factors associated with QOL change were evaluated using exploratory regression analyses and a clinically informed multivariable linear regression model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Following the treatment period, mean QOL scores improved significantly. In the clinically informed multivariable model, baseline EQ-5D, number of remaining teeth, serum tartrate-resistant acid phosphatase 5b levels, and corrected urinary pentosidine levels were independently associated with the change in EQ-5D from baseline to 72\u00a0weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identified several clinical and biochemical factors associated with QOL improvement in patients undergoing treatment for severe osteoporosis. These findings suggest that baseline QOL, oral health status, and biochemical markers of bone turnover and bone quality may be associated with QOL improvement during osteoporosis treatment. Further studies are needed to validate these exploratory findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00774-026-01764-6","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:57:15Z","timestamp":1791259035000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors associated with improved quality of life in severe osteoporosis: a post hoc analysis of JOINT-05"],"prefix":"10.1007","author":[{"given":"Hiroyuki","family":"Inose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Hagino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Soen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"1764_CR1","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/s0140-6736(18)32112-3","volume":"393","author":"JE Compston","year":"2019","unstructured":"Compston JE, McClung MR, Leslie WD (2019) Osteoporosis (in eng). Lancet 393:364\u2013376. https:\/\/doi.org\/10.1016\/s0140-6736(18)32112-3","journal-title":"Lancet"},{"key":"1764_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00774-004-0556-5","volume":"23","author":"K Yoh","year":"2005","unstructured":"Yoh K, Tanaka K, Ishikawa A, Ishibashi T, Uchino Y, Sato Y, Tobinaga M, Hasegawa N, Kamae S, Yoshizawa M (2005) Health-related quality of life (HRQOL) in Japanese osteoporotic patients and its improvement by elcatonin treatment (in eng). J Bone Miner Metab 23:167\u2013173. https:\/\/doi.org\/10.1007\/s00774-004-0556-5","journal-title":"J Bone Miner Metab"},{"key":"1764_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s001980050210","volume":"10","author":"P Lips","year":"1999","unstructured":"Lips P, Cooper C, Agnusdei D, Caulin F, Egger P, Johnell O, Kanis JA, Kellingray S, Leplege A, Liberman UA, McCloskey E, Minne H, Reeve J, Reginster JY, Scholz M, Todd C, de Vernejoul MC, Wiklund I (1999) Quality of life in patients with vertebral fractures: validation of the quality of Life questionnaire of the European foundation for osteoporosis (QUALEFFO). working party for quality of life of the European foundation for osteoporosis (in eng). Osteoporos Intern: J established Result Cooper Between European Found Osteoporos National Osteoporos Found USA 10:150\u2013160. https:\/\/doi.org\/10.1007\/s001980050210","journal-title":"Osteoporos Int"},{"key":"1764_CR4","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s11136-022-03281-1","volume":"32","author":"S Gao","year":"2023","unstructured":"Gao S, Zhao Y (2023) Quality of life in postmenopausal women with osteoporosis: a systematic review and meta-analysis (in eng). Qual Life Res 32:1551\u20131565. https:\/\/doi.org\/10.1007\/s11136-022-03281-1","journal-title":"Qual Life Res"},{"key":"1764_CR5","doi-asserted-by":"publisher","first-page":"E1333","DOI":"10.1503\/cmaj.221647","volume":"195","author":"SN Morin","year":"2023","unstructured":"Morin SN, Feldman S, Funnell L, Giangregorio L, Kim S et al (2023) Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update (in eng). CMAJ 195:E1333\u2013E1348. https:\/\/doi.org\/10.1503\/cmaj.221647","journal-title":"CMAJ"},{"key":"1764_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10245961","author":"H Inose","year":"2021","unstructured":"Inose H, Kato T, Shirasawa S, Takahashi S, Hoshino M, Yamato Y, Matsukura Y, Hirai T, Yoshii T, Okawa A (2021) Time course of acute vertebral fractures: a prospective multicenter cohort study (in eng). J clin Med. https:\/\/doi.org\/10.3390\/jcm10245961","journal-title":"J Clin Med"},{"key":"1764_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10191","volume":"3","author":"S Hayashi","year":"2019","unstructured":"Hayashi S, Fukuda K, Maeda T, Chinzei N, Kihara S, Miura Y, Sakai Y, Hashimoto S, Matsumoto T, Takayama K, Niikura T, Kuroda R (2019) Denosumab treatment improved health-related quality of life in osteoporosis: a prospective cohort study (in eng). JBMR Plus 3:e10191. https:\/\/doi.org\/10.1002\/jbm4.10191","journal-title":"JBMR Plus"},{"key":"1764_CR8","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.21037\/apm-20-2333","volume":"10","author":"Z Chen","year":"2021","unstructured":"Chen Z, Lin W, Zhao S, Mo X, Yuan W, Cheung WH, Fu D, Chen B (2021) Effect of Teriparatide on pain relief, and quality of life in postmenopausal females with osteoporotic vertebral compression fractures, a retrospective cohort study (in eng). Ann Palliat Med 10:4000\u20134007. https:\/\/doi.org\/10.21037\/apm-20-2333","journal-title":"Ann Palliat Med"},{"key":"1764_CR9","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1007\/s00198-010-1495-8","volume":"22","author":"J Iwamoto","year":"2011","unstructured":"Iwamoto J, Makita K, Sato Y, Takeda T, Matsumoto H (2011) Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis (in eng). Osteoporos Intern: J Established Result Cooper Between European Found Osteoporos National Osteoporos Found USA 22:2735\u20132742. https:\/\/doi.org\/10.1007\/s00198-010-1495-8","journal-title":"Osteoporos Int"},{"key":"1764_CR10","doi-asserted-by":"publisher","first-page":"442","DOI":"10.12659\/msm.881905","volume":"17","author":"A Panico","year":"2011","unstructured":"Panico A, Lupoli GA, Marciello F, Lupoli R, Cacciapuoti M, Martinelli A, Granieri L, Iacono D, Lupoli G (2011) Teriparatide vs alendronate as a treatment for osteoporosis: changes in biochemical markers of bone quality of. Med Sci Monitor: Intern Medical J Exp Clin Res 17:442\u2013448. https:\/\/doi.org\/10.12659\/msm.881905","journal-title":"Med Sci Monit"},{"key":"1764_CR11","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00198-021-05996-2","volume":"32","author":"H Hagino","year":"2021","unstructured":"Hagino H, Sugimoto T, Tanaka S, Sasaki K, Sone T, Nakamura T, Soen S, Mori S (2021) A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05 (in eng). Osteoporos Intern: J Established Result Cooper Between European Found Osteoporos National Osteoporos Found USA 32:2301\u20132311. https:\/\/doi.org\/10.1007\/s00198-021-05996-2","journal-title":"Osteoporos Int"},{"key":"1764_CR12","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s00774-019-01074-0","volume":"38","author":"S Tanaka","year":"2020","unstructured":"Tanaka S, Mori S, Hagino H, Sugimoto T (2020) Design of a randomized trial of teriparatide followed by alendronate: Japanese osteoporosis intervention trial-05 (JOINT-05) (in eng). J Bone Miner Metab 38:412\u2013417. https:\/\/doi.org\/10.1007\/s00774-019-01074-0","journal-title":"J Bone Miner Metab"},{"key":"1764_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3177\/jnsv.54.25","volume":"54","author":"K Uenishi","year":"2008","unstructured":"Uenishi K, Ishida H, Nakamura K (2008) Development of a simple food frequency questionnaire to estimate intakes of calcium and other nutrients for the prevention and management of osteoporosis (in eng). J Nutr Sci Vitaminol (Tokyo) 54:25\u201329. https:\/\/doi.org\/10.3177\/jnsv.54.25","journal-title":"J Nutr Sci Vitaminol (Tokyo)"},{"key":"1764_CR14","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s11136-004-7713-0","volume":"14","author":"SJ Walters","year":"2005","unstructured":"Walters SJ, Brazier JE (2005) Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D (in eng). Qual Life Res 14:1523\u20131532. https:\/\/doi.org\/10.1007\/s11136-004-7713-0","journal-title":"Qual Life Res"},{"key":"1764_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11136-020-02629-9","volume":"30","author":"H Inose","year":"2020","unstructured":"Inose H, Kato T, Nakamura H, Hoshino M, Togawa D et al (2020) Predictors for quality of life improvement after acute osteoporotic vertebral fracture: results of post hoc analysis of a prospective randomized study (in eng). Qual Life Res. https:\/\/doi.org\/10.1007\/s11136-020-02629-9","journal-title":"Qual Life Res"},{"key":"1764_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/nu11122898","author":"D Azzolino","year":"2019","unstructured":"Azzolino D, Passarelli PC, De Angelis P, Piccirillo GB, D\u2019Addona A, Cesari M (2019) Poor oral health as a determinant of malnutrition and sarcopenia (in eng). Nutrients. https:\/\/doi.org\/10.3390\/nu11122898","journal-title":"Nutrients"},{"key":"1764_CR17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1017\/s0007114521000180","volume":"126","author":"E Kotronia","year":"2021","unstructured":"Kotronia E, Brown H, Papacosta AO, Lennon LT, Weyant RJ, Whincup PH, Wannamethee SG, Ramsay SE (2021) Poor oral health and the association with diet quality and intake in older people in two studies in the UK and USA. Br J Nutr 126:118\u2013130. https:\/\/doi.org\/10.1017\/s0007114521000180. ((in eng))","journal-title":"Br J Nutr"},{"key":"1764_CR18","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.jamda.2021.01.058","volume":"22","author":"W Ito","year":"2021","unstructured":"Ito W, Komiyama T, Ohi T, Hiratsuka T, Matsuyama S, Sone T, Tsuji I, Watanabe M, Hattori Y (2021) Relationship between oral health and fractures in community-dwelling older Japanese adults. J Am Med Dir Assoc 22:1184\u201389.e1. https:\/\/doi.org\/10.1016\/j.jamda.2021.01.058. ((in eng))","journal-title":"J Am Med Dir Assoc"},{"key":"1764_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2023.116880","volume":"176","author":"B Wang","year":"2023","unstructured":"Wang B, Vashishth D (2023) Advanced glycation and glycoxidation end products in bone. Bone 176:116880. https:\/\/doi.org\/10.1016\/j.bone.2023.116880. ((in eng))","journal-title":"Bone"},{"key":"1764_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11914-014-0202-7","volume":"12","author":"M Saito","year":"2014","unstructured":"Saito M, Kida Y, Kato S, Marumo K (2014) Diabetes, collagen, and bone quality. Curr Osteoporos Rep 12:181\u2013188. https:\/\/doi.org\/10.1007\/s11914-014-0202-7. ((in eng))","journal-title":"Curr Osteoporos Rep"},{"key":"1764_CR21","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1111\/jdi.13581","volume":"12","author":"X Zhang","year":"2021","unstructured":"Zhang X, Liu J, Zhang Q, Lu A, Du Y, Ye X (2021) Elevated serum pentosidine is independently associated with the high prevalence of sarcopenia in Chinese middle-aged and elderly men with type 2 diabetes mellitus. J Diabetes Investig 12:2054\u20132061. https:\/\/doi.org\/10.1111\/jdi.13581. ((in eng))","journal-title":"J Diabetes Investig"},{"key":"1764_CR22","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/s0026-0495(03)00310-x","volume":"52","author":"H Tsukahara","year":"2003","unstructured":"Tsukahara H, Shibata R, Ohta N, Sato S, Hiraoka M, Ito S, Noiri E, Mayumi M (2003) High levels of urinary pentosidine, an advanced glycation end product, in children with acute exacerbation of atopic dermatitis: relationship with oxidative stress. Metabolism 52:1601\u20131605. https:\/\/doi.org\/10.1016\/s0026-0495(03)00310-x","journal-title":"Metabolism"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-026-01764-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-026-01764-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-026-01764-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:57:16Z","timestamp":1791259036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-026-01764-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":22,"alternative-id":["1764"],"URL":"https:\/\/doi.org\/10.1007\/s00774-026-01764-6","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H Inose received speaking fees from Astellas Pharma Inc., Amgen Inc., Asahi Kasei Pharma Corp., Teijin Pharma Ltd., and Daiichi Sankyo Co. S Mori has received speaking fees from Amgen Inc., Asahi Kasei Pharma Corp., and Astellas Pharma Inc. H Hagino has received lecture fees or grants from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Mochida Pharma Co., Ltd., Kyowa Kirin Co., Ltd, Teijin Pharma Ltd., and UCB Japan Co., Ltd. S Soen has received consulting fees, speaking fees, and\/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}